Nelarabine is an antineoplastic agent approved for the treatment of relapsed/refractory T-lineage acute lymphoblastic leukaemia (T-ALL) or T-lineage acute lymphoblastic lymphoma (T-LBL). The purpose of this phase 4, multicentre, single-arm, observational, open-label trial was to provide additional data on the safety and efficacy of nelarabine under licensed conditions of use in children and young adults ≤21 years of age. Patients (N = 28) had a mean AE standard deviation age of 11Á5 AE 4Á6 years; 71% were male and 61% had a diagnosis of T-ALL. Adverse events (AEs) and treatment-related AEs were experienced by 46% and 21%, respectively, and included few haematological AEs and no haematological serious AEs. Neurological AEs from one of four predefined categories (peripheral and central nervous systems, mental status change and uncategorized) were reported in four patients. There were no AE-related treatment discontinuations/withdrawals. The overall response rate was 39.3%: complete response (CR), 35.7%; CR without full haematological recovery (CR*), 3.6%. Posttreatment stem cell transplantation was performed for 46% of the cohort. Median overall survival (OS) was 3Á35 months for non-responders and not reached for responders (CR + CR*). The response rate, median OS, and safety profile of nelarabine in this disease setting and population were consistent with those reported previously.
Acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) are lymphoblastic neoplasms that are highly aggressive in paediatric patients and can be rapidly fatal in the absence of effective therapy (Reiter, 2013; National Comprehensive Cancer Network, 2015) . These neoplasms are of either B-or T-cell origin, of which the T-cell lineage (T-ALL and T-LBL) has been reported to be more aggressive (Elreda et al, 2014; You et al, 2015) . While biologically very similar, T-ALL and T-LBL differ primarily by the extent of bone marrow involvement, which is either absent or minimal in T-LBL and extensive in T-ALL (Van Vlierberghe & Ferrando, 2012; Burkhardt et al, 2016) .
The mainstay of treatment for both T-ALL and T-LBL is multiagent chemotherapy and/or stem cell transplantation (SCT) in patients considered at high risk for relapse or resistant disease (Minard-Colin et al, 2015; Bassan et al, 2016) . Prognosis in T-ALL is impacted by several factors, including age, central nervous system (CNS) involvement, certain chromosomal/genetic abnormalities and minimal residual disease status (Pui et al, 2011 (Pui et al, , 2015 National Cancer Institute, 2017) . Young adults and older adolescents have a poorer prognosis than their younger counterparts (Pui et al, 2011) . The 5-year overall survival (OS) for young adults and adolescents is 42-63%, while for children it is 86-89% (National Comprehensive Cancer Network, 2015; Pui et al, 2015) . The only clinical prognostic factor in T-LBL identified to date is stage (localized versus advanced), although a trend toward a better prognosis has been reported among patients with a good response to 7 days of corticosteroids or a radiological response at 2 weeks (Minard-Colin et al, 2015; National Cancer Institute, 2016) . Burkhardt et al (2009) reported an 11% rate of relapse or disease progression among 251 paediatric patients with T-LBL; the prognosis of these patients is often poor, with survival rates of 10-30% (Burkhardt et al, 2016) .
Deoxyguanine and its derivate 9-b-D-arabinofuranosylguanine (ara-G) are toxic to T lymphocytes via inhibition of DNA synthesis (Cohen et al, 1983) . Nelarabine is a water-soluble prodrug of ara-G that has been evaluated as a treatment for refractory or relapsed T-ALL and T-LBL in two phase 2 studies (Berg et al, 2005; DeAngelo et al, 2007;  http://www.ema.eu ropa.eu/docs/en_GB/document_library/EPAR_-_Product_Inf ormation/human/000752/WC500027918.pdf; National Comprehensive Cancer Network, 2015) . Daily monotherapy with nelarabine at a dose of 650 mg/m 2 [intravenous (IV)] over 1 h for 5 consecutive days yielded a complete response (CR) rate of 13% [95% confidence interval (CI) 4-27%] in paediatric patients (treated with ≥2 prior induction therapies) (N = 39); the response rate for patients with or without full haematological recovery was 23% (95% CI 11-39%) (http://www.ema.eu ropa.eu/docs/en_GB/document_library/EPAR_-_Product_Inf ormation/human/000752/WC500027918.pdf). Similar adult cohorts treated with 1500 mg/m 2 nelarabine (IV) over 2 h on days 1, 3 and 5 (N = 8) experienced a CR rate of 18% (95% CI 6-37%) and 21% (95% CI 8-41%) with or without haematological recovery (http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/ 000752/WC500027918.pdf). Similar to other drugs in its class, nelarabine is associated with haematological adverse events (AEs), including neutropenia, thrombocytopenia and anaemia (DeAngelo et al, 2007) . Neurological toxicity has been a major concern; grade ≥3 neurological toxicities have been reported in 18% of children and young adults (Berg et al, 2005) . Severe neurological-associated AEs included altered mental states, CNS effects and peripheral neuropathies (Berg et al, 2005) ; the reversibility of these AEs has not been assessed. There have also been reports of events associated with demyelination and ascending peripheral neuropathies similar in appearance to Guillain-Barr e syndrome (Berg et al, 2005) . Prior cranial radiation or intrathecal chemotherapy may increase the risk of neurotoxicity with nelarabine (DeAngelo et al, 2007; Bauters et al, 2011) .
In vitro studies of ara-G (biotransformed nelarabine) in tumour cell samples from treatment-na€ ıve paediatric patients with T-ALL, B-cell precursor ALL (BCP-ALL) and acute myeloid leukaemia (AML) demonstrated a selective T-cell toxicity in T-ALL paediatric samples (Homminga et al, 2011) . The value of the median concentration lethal to 50% of the population (LC 50 ) with nelarabine for T-cell samples from primary T-ALL patients was 20Á5 lmol/l ara-G; LC 50 was above values that could be determined within this assay for approximately 50% of the BCP-ALL and AML samples (Homminga et al, 2011) . Furthermore, there was no evidence of antagonism between nelarabine and any of the drugs currently used in leukaemia therapy (Homminga et al, 2011) .
The objective of the current phase 4 study was to provide additional data on the safety and efficacy of nelarabine (650 mg/m 2 ) under licensed conditions of use in children and young adults ≤21 years of age with relapsed or refractory T-ALL or T-LBL who were refractory to, or had relapsed following, treatment with ≥2 chemotherapy regimens.
Materials and Methods

Study design
This was an international, multicentre, single-arm, observational, open-label phase 4 study that was conducted at 17 sites throughout 8 countries (NCT00866671). The study protocol was reviewed by national, regional or investigational centre ethics committees or institutional review boards in accordance with the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and the Declaration of Helsinki. Written informed consent to participate was obtained from each patient or his or her parents or legal representative before commencement of the study. Patients received at least one cycle of nelarabine obtained from commercial stock as monotherapy, with each cycle consisting of the recommended daily dose of 650 mg/m 2 IV over 1 h for 5 consecutive days, repeated every 21 days. The decision regarding the duration of treatment was made by the investigator based on several factors, including tolerability, disease response and the availability of subsequent treatment options, such as SCT. There was no defined maximum number of nelarabine cycles. Nelarabine was to be discontinued at the first sign of neurological events of grade 2 or higher severity, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 (NCI CTCAE v3.0; http://ctep.cancer.gov/protocolDe velopment/electronic_applications/docs/ctcaev3.pdf). Dosing delays could be imposed in the event of other toxicities, including haematological toxicities. Withdrawal of nelarabine treatment did not constitute withdrawal from the study. All patients were followed for 1 year from the start of treatment.
Patients
The original study plan (based on feasibility) was to enrol approximately 40 paediatric and young adult (<21 years of age) male and female patients with relapsed or refractory T-ALL or T-LBL disease following treatment with ≥2 chemotherapy regimens; this number reflects the very low number of patients with the disease. However, because of recruitment difficulties that are probably attributable to both the small available population and the recent implementation of a study of nelarabine in combination with other therapeutics as a treatment mode in this patient group [i.e. NECTAR, NCT00981799 (Whitlock et al, 2014) ], the actual number of patients enrolled was only 28.
Patients were excluded from the study if they had a known hypersensitivity to the active substance or persistent neurological toxicity (grade ≥2; regardless of aetiology), were adolescents (aged ≥16 years) or adults for whom the physician had prescribed the 1500 mg/m 2 adult dose of nelarabine or, as a result of a specific amendment for French patients, had participated in any study using an investigational drug during the previous 30 days or 5 half-lives of the investigational drug (whichever was longer).
Disease response
Disease response was determined by investigator and categorized as complete response (CR), complete response without haematological recovery (CR*), partial response (PR), no response (NR) or progressive disease (PD). A complete response was defined as bone marrow with blast counts of ≤5% (M1) and no evidence of extramedullary disease. Complete haematological recovery (CR) was defined as absolute neutrophil count >1Á5 9 10 9 /l, platelets >100 9 10 9 /l, haemoglobin ≥100 g/l for patients <2 years of age, or ≥110 g/l for patients ≥2 years of age, based on peripheral blood count. CR* was defined as CR with no other evidence of disease but with incomplete haematological recovery. PR was defined as bone marrow blast count >5% but ≤25% (M2) and/or persistent evidence of extramedullary disease and a reduction of total lymphoma volume of >50%, no evidence of progression and no new lesions for >3 weeks. NR was defined as bone marrow blast count >25% (M3), blasts in peripheral blood, failure of haematological recovery, or persistent evidence of extramedullary disease not meeting PR criteria. PD was determined by the presence of one or more of: new clinical symptoms, new appearance of blasts in the peripheral blood, deterioration of bone marrow from M1 to M2/M3 or from M2 to M3, new appearance of extramedullary disease manifestations and increase in the volume of any lesion or in the total lymphoma volume of >25%.
Response was evaluated at the end of each treatment cycle, the end of therapy (28 days after last treatment cycle or early withdrawal) and during follow-up for up to 12 months after the start of treatment.
Neurological examination
Neurological examinations were conducted at every visit from baseline (pre-treatment), at the end of each treatment cycle, end of therapy (28 days after last treatment cycle or early withdrawal) and during follow-up for up to 12 months after the start of treatment. The following neurological parameters were tested: reflexes, motor function, coordination, gait, mental status, cranial nerve function and sensory function.
Efficacy and safety endpoints
Efficacy. The primary efficacy endpoint was the overall response rate (ORR), defined as the proportion of patients with a CR or CR* as a best response determined by the investigator. Other efficacy endpoints included CR duration (the time from CR or CR* to the date of PD or death), OS (time from the date of the first dose of study drug to the date of death), and survival rate at 1 year (proportion of patients who received ≥1 dose of study drug alive at 1 year after their first dose). For the purposes of the current analysis, non-responders were considered to be patients with partial responses, no responses, disease progression or not evaluable. Subsequent anti-leukaemia/-lymphoma treatment, including SCT, and its outcome were recorded.
Safety. Safety endpoints were the frequencies (n [%]) of neurological and nonneurological AEs and serious AEs (SAEs), which were monitored at each visit. The severity of AEs/SAEs (graded according to NCI CTCAE v3.0), probable causality, duration and action taken were all recorded. SAEs occurring up to 28 days after the last dose of nelarabine were recorded, and for up to 1 year after the first dose of nelarabine thereafter.
Because neurotoxicity is a recognized AE of nelarabine therapy, a primary focus of this study was to carefully identify and characterize any neurological toxicity that occurred. In addition to the standard collection of AEs on study, a thorough neurological examination and data collection process were employed to enhance the study's sensitivity to detect changes in neurological status during, and up to 1 year following, nelarabine treatment. All patients were to receive CNS prophylaxis as standard of care (at the discretion of the investigator).
Statistical analysis
Demographic data, including age, race, ethnicity, sex, height, body weight and baseline disease characteristics, are summarised. Summary statistics [i.e. mean, standard deviation (SD), median, minimum, maximum] were computed for the continuous variables, while frequencies [n (%)] were calculated for categorical variables.
The efficacy analyses were conducted using data from the intention-to-treat (ITT) population (all patients who were enrolled in the study). Survival distributions were estimated for both the CR and CR* populations using the KaplanMeier method. Post hoc analysis of OS was also reported according to best overall response (i.e. CR + CR* versus all other responses).
ORR (at best response; CR + CR*) and SCT rate (percentage of patients who underwent SCT following nelarabine therapy) were calculated. Descriptive summaries of the types of SCT (allogeneic versus autologous regimen; myeloablative versus nonmyeloablative regimen), outcome (proportion alive with/without complete remission, dead or lost to follow-up) and stem cell donor status were recorded.
The safety analyses were conducted using the safety population (all patients who received ≥1 dose of nelarabine). AEs were coded using preferred terms in the Medical Dictionary for Regulatory Activities (MedDRA) v17.0 (https://www. meddra.org/). All AEs and treatment-related AEs (TRAEs) were summarized. Neurologically associated AEs were prospectively assigned to one of four categories: peripheral nervous system (PNS), CNS, mental status changes (MSC) and uncategorized neurological events.
Subgroup analyses by demographics and dosing regimen were planned; however, the achievement of clinically meaningful differences between the various subgroups was limited by the small patient numbers in these subgroups.
All data analyses were performed using SAS software, v 9.3 (SAS Institute, Cary, NC, USA); data are presented as mean AE SD, median (range) or frequencies (n and %).
Results
Patient population
The ITT and safety populations comprised 28 patients. The first patient was enrolled on 2 February 2009; the last patient completed the study on 28 August 2014. Ten of 28 patients (36%) completed the study (including 1 year of follow-up after the first dose of the study drug); 17 patients died (61%) within the 1-year follow-up period, as a result of progressive disease (n = 13), a potentially treatment-related SAE (n = 2), sepsis or multiorgan failure (n = 1) and transplantationrelated toxicity (n = 1). One patient was lost to follow-up.
Most patients were male (71%; n = 20) and white (64%; n = 18), and the entire cohort had a mean AE SD age of 11Á5 AE 4Á6 years (range 3-22 years). The majority (61%; n = 17) had T-ALL as their initial diagnosis (Table I) .
Safety and exposure
Exposure to nelarabine was calculated based on the standard 21-day dosing regimen cycle, which included 5 sequential days of nelarabine administration followed by 16 days without. The mean exposure to nelarabine was 19Á6 AE 29Á0 days (median 5Á0 days; range 5-154 days), and most patients had 1 (57%) or 2 cycles (36%) of the study drug; 1 patient had 3 cycles and 1 patient had 5 cycles. Most patients (93%) received the standard 650 mg/m 2 nelarabine dose as monotherapy; however, 1 patient received <650 mg/m 2 as monotherapy and another received <650 mg/m 2 in combination with other chemotherapy. These were noted as protocol violations. Overall, the AEs reported were consistent with the known safety profile of nelarabine and the disease studied. Thirteen patients (46%) experienced an AE, and 6 patients (21%) reported TRAEs. AEs by preferred term in at least 2 patients included paresthesia and pyrexia [n = 3 (11%) for each], and anaemia, nausea, neutropenia and thrombocytopenia [n = 2 (7%) for each]. There were no AE-related treatment discontinuations or study withdrawals.
Four patients (14%) experienced SAEs, which included encephalopathy, multiorgan failure, VIIth nerve paralysis and Pneumocystis jirovecii pneumonia (n = 1 for each). Two of these events were grade 5 (led to death). One patient died as a result of encephalopathy occurring at day 98 (94 days after the last dose of study drug), which was suspected to be related to nelarabine, and another died from multiorgan failure at day 88 (84 days after the last dose of study drug), CNS, central nervous system; SD, standard deviation; T-ALL, T-lineage acute lymphoblastic leukaemia; T-LBL, T-lineage acute lymphoblastic lymphoma. *All 9 patients of unknown race were enrolled at centres in France where race data could not be collected for legal reasons. †All 3 stem cell transplantations were allogeneic.
Nelarabine in Relapsed/Refractory Lymphoblastic Leukaemia ª 2017 John Wiley & Sons Ltd which was not thought to be related to nelarabine. The patient who died from encephalopathy had received one 5-day cycle of nelarabine. He had no prior radiation or SCT. Three days after starting nelarabine, he experienced peripheral sensory neuropathy, and 3 days later he developed peripheral motor neuropathy. Grade 4 encephalopathy developed 94 days after the last dose of nelarabine. Because of ongoing refractory disease, this patient had been irradiated on the chest and subsequently conditioned for SCT, including total body irradiation and CNS irradiation. The patient died as a result of encephalopathy 128 days after the last dose of nelarabine. The investigator considered the event possibly related to nelarabine and possibly due to total body irradiation for SCT, including CNS irradiation. Another patient had an SAE of VIIth (facial motor) nerve paralysis that occurred on the first day of the study and was considered grade 3 and treatment related. This patient recovered from this event over a 24-day period with dose reduction (but not withdrawal) of nelarabine. The final SAE was grade 3 Pneumocystis jirovecii pneumonia that occurred on day 168, from which the patient recovered over a 3-week period following antibiotic treatment; this event was not thought to be treatment-related. A list of grade 3-5 AEs and on-study deaths can be found in Tables II and III , respectively.
Neurological effects. Five patients (18%) experienced AEs associated with the nervous system, of whom 4 had neurologically associated AEs belonging to 1 of the 4 predefined categories: 2 patients had paresthesia (PNS category); 1 patient had VIIth nerve paralysis (CNS category); and the fourth patient had neurological AEs in all 4 categories-peripheral neuropathy, paresthesia (PNS category), aphasia, encephalopathy, paralysis (CNS category), somnolence (MSC) and abasia (uncategorized). The 2 patients with paraesthesia and the patient with VIIth nerve paralysis recovered from these events. The patient with multiple neurological AEs died from encephalopathy. A fifth patient reported an AE of headache, but was not included in the neurologically associated categories according to the analysis plan. Serial neurological evaluations revealed deterioration from baseline in 7 (25%) patients. These symptoms resolved or partially resolved in 5 of the 7 patients. One patient had multiple neurological abnormalities (decreases in motor strength, reflexes, coordination, sensory function, abnormal gait and abnormal cranial function at day 21) that did not resolve at the last assessment on day 51, and 1 patient had decreased reflexes at day 27 (1 day after the last dose) and did not have any follow-up assessments performed. Worsening of reflexes was observed in 5 patients (18%). Reflexes returned to normal in 3 of these 5 patients after treatment cessation; 1 patient had diminished reflexes at baseline and reflexes were absent at the end of cycle 1 (day 22), but at the end of cycle 3 (day 61) the symptoms had resolved and normal reflexes were noted. A second patient had diminished motor reflexes but normal sensory function, coordination, and gait at baseline; each became abnormal (or absent, for reflexes) at or before day 23 and all resolved by day 28 (24 days after the last dose of nelarabine). The third patient had absent reflexes 25 days after the last dose of nelarabine; these reflexes returned to normal by 61 days after treatment. Only 2 of the 7 patients with worsening on neurological examination had an event noted as a neurological AE.
Overall, 20 of the 28 patients had at least 1 risk factor that may increase the neurotoxicity of nelarabine; however, only 4 of the 9 patients with a neurological effect (either as an AE or detected on neurological examination) had one or more of those risk factors: prior CNS involvement (n = 1), prior radiation (n = 1), prior radiation and prior or concomitant intrathecal therapy (n = 1) and prior CNS involvement and prior or concomitant intrathecal therapy (n = 1). Three of these 4 patients had findings only reported as neurological examination changes. Cause of death n (%)
Deaths within 28 days of last dose 4 (14) Underlying disease 4 (14) Deaths more than 28 days after last dose 13 (46) Underlying disease 9 (32) SAE possibly related to treatment* 2 (7) Sepsis, multiorgan failure 1 (4) Toxicity due to SCT 1 (4) SAE, serious adverse event; SCT, stem cell transplantation. *One patient had died from an SAE of encephalopathy considered as possibly related to treatment. The data for the other patient were entered incorrectly; he had died as a result of an SAE, multiorgan failure, which was not related to study treatment.
Efficacy
The ORR was 39.3% (n = 11); 35.7% (n = 10) had CR and 3.6% (n = 1) had CR*. The response of 13 of the 28 patients (46%) was sufficient to enable them to ultimately proceed to post-treatment SCT; 10 patients in this group ceased nelarabine while responding to the drug (i.e. these patients had achieved CR at time of drug cessation) in order to receive the procedure. Ten of the 13 patients were alive at the 1-year follow-up, and 7 were in complete remission. SCT was performed immediately following nelarabine therapy in 9 of the 11 responders and 2 of the 17 non-responders. At last contact (prior to the study complete date of 28 August 2014), 17 (61%) patients had died and the remaining 11 (39%) were still alive; the median OS was 6Á5 months (95% CI 3Á1-not reached; Fig 1A) . Of those 11 patients, 10 were alive 1 year after study start, and 1 patient was censored at 9Á4 months and lost to follow-up. The median time to an event (defined as progression, death due to any cause, administration of next therapy, radiotherapy, post-therapy SCT or last contact date) was 1Á31 months (95% CI 0Á56-2Á00) from first dose (Fig 1B) . A post hoc survival analysis summarized by response demonstrated a median survival that was not reached for the responders (n = 11) versus 3Á35 months for the nonresponders (n = 17; Fig 2) .
Follow-up treatment
After discontinuing nelarabine therapy, 15 (54%) of the patients received additional anti-leukaemia therapy during the follow-up phase: 14 (50%) received chemotherapy, 2 (7%) received hormonal therapy and 5 (18%) received immunotherapy.
Discussion
The data supporting the approval of nelarabine for the treatment of patients (including paediatric patients) with relapsed/refractory T-ALL and T-LBL subsequent to at least 2 chemotherapy regimens are limited because of small patient numbers (National Cancer Institute, 2013; National Comprehensive Cancer Network, 2015; http://www.ema.europa.eu/d ocs/en_GB/document_library/EPAR_-_Product_Information/ human/000752/WC500027918.pdf). The most frequently occurring AEs associated with nelarabine at the recommended dose (650 mg/m 2 IV for 5 consecutive days in 3-week cycles for paediatric patients) are fatigue and gastrointestinal, haematological, respiratory and nervous system disorders (http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/000752/WC500 027918.pdf). Its dose-limiting toxicity is neurotoxicity, some manifestations of which appear to be irreversible upon cessation of the drug (http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/ 000752/WC500027918.pdf; Gollard & Selco, 2013; Kurtzberg et al, 2005) . The risk of neurotoxicity may be greater in patients with a history of intrathecal chemotherapy or craniospinal irradiation (Bauters et al, 2011) . The population evaluated in this study was representative of the licensed indication of nelarabine (http://www.ema. europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/000752/WC500027918.pdf). Most patients had received ≥2 prior chemotherapy regimens and most received 1 or 2 cycles of nelarabine during the study period. Discontinuations generally occurred because of PD or a favourable response suitable for subsequent SCT.
A response (CR/CR*) was observed in 39% (n = 11/28) of patients, which is higher than the CR + CR* rates reported for similar adult and paediatric cohorts in phase 2 studies (21% and 36%, respectively) (http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/ human/000752/WC500027918.pdf). In addition, approximately 35% (n = 10/28) of patients were alive at the 1-year follow-up (7 were in complete remission), which is also higher than the previously reported 1-year survival rates (29% and 14%, in the respective studies) (http://www.ema.eu ropa.eu/docs/en_GB/document_library/EPAR_-_Product_Inf ormation/human/000752/WC500027918.pdf). Historical outcome data from a review by the Children's Oncology Group (COG) before the introduction of nelarabine identified 13 patients with relapsed or refractory disease following ≥2 induction attempts; all 13 patients were dead by 8 months after diagnosis (GlaxoSmithKline, unpublished data). Indicative of the efficacy of nelarabine in this patient population, the response of almost half of the patients in the present study was sufficient to qualify them for post-treatment SCT. Fewer than half of the patients reported an AE, and none discontinued the study because of an AE. The recorded AEs were consistent with the known safety profile of nelarabine and the patient population under study. The level of haematological toxicity was relatively low in this patient population, with AEs such as neutropenia, anaemia and thrombocytopenia being reported in 2 patients each; no haematological SAEs were recorded. This is particularly important in these heavily pre-treated patients. Two SAEs resulted in death; one of these (encephalopathy) was considered to be treatment-related.
Neurotoxicity is a recognized treatment-related AE of nelarabine therapy. Thus, the identification and careful characterization of any neurological toxicity on study was enabled by conducting serial neurological examinations, in addition to the standard collection of AEs. This enhanced the sensitivity of the study to detect changes in the patients' neurological status, both during and up to 1 year following nelarabine treatment. Most patients did not suffer neurologically associated AEs. Nine patients had some evidence of a neurological effect, either as an AE (n = 2) or as a deterioration in neurological examination findings (n = 7), including 2 patients who had a neurological AE with no deterioration from baseline. Most of the abnormal neurological findings seen upon examination appeared to be reversible upon cessation of nelarabine. The majority of the study population (20/28) had at least 1 known risk factor for nelarabine-associated neurological toxicities (e.g. CNS disease, prior or concurrent intrathecal therapy and prior CNS radiation therapy (DeAngelo et al, 2007; Bauters et al, 2011) . However, these risks did not appear to be predictive of neurotoxicity in this population; 5 of the 9 patients with neurological changes did not possess any of these risk factors. Moreover, in 3 of the 4 patients with neurological findings who did have 1 or more of these risk factors, the neurological findings were identified as neurological examination changes and not as AEs. None of the remaining 16 patients with risk factors for neurological toxicity experienced neurological toxicity during the 1-year follow-up period.
The data from several clinical trials, including the present study, have demonstrated that when administered as a monotherapy, nelarabine can induce both CRs and PRs in paediatric and adult patients with T-ALL and T-LBL (Berg et al, 2005; Kurtzberg et al, 2005; DeAngelo et al, 2007) . In addition, the safety and feasibility of using nelarabine in a combination scenario in a paediatric population has also been established in a pilot study [Children's Oncology Group (COG) study AALL00P2] in which young patients (aged 1--22 years) with newly diagnosed T-ALL received a BerlinFrankfurt-M€ unster (BFM)-based chemotherapy regimen with or without nelarabine. It was demonstrated that the addition of five or six 5-day courses of nelarabine at 400 or 650 mg/m 2 to a BFM-based chemotherapy regimen was associated with acceptable levels of toxicity (only 1 of the 72 patients experienced a neurological AE clearly related to nelarabine treatment, which was Guillain-Barr e-like syndrome) (Dunsmore et al, 2012) . Although not sufficiently powered to enable firm conclusions to be drawn, the efficacy data in that study were described as encouraging: high-risk patients (defined according to a prednisone poor response or minimal residual disease ≥1% at induction therapy day 36) who received chemotherapy plus nelarabine had a 5-year event-free survival rate that was similar to that of their lowrisk counterparts who received chemotherapy alone (69%); that figure for low-risk patients who received both nelarabine and chemotherapy was 74% (Dunsmore et al, 2012 ). An open-label, international, randomised, active-control, phase 3 trial is also currently being conducted to determine the safety and efficacy of nelarabine as a component of a COG-augmented BFM (aBFM) regimen in paediatric and young adult patients (aged 1-30 years) with treatment-na€ ıve T-ALL or T-LBL (NCT00408005). The recently published first-phase safety data from that trial demonstrated that the combinations of Capizzi-style escalating intravenous methotrexate or high-dose methotrexate plus six 5-day courses of nelarabine during the interim maintenance phase are safe, with no differences in the incidences of peripheral or sensory neuropathies or in central neurotoxicity relative to the comparator arms without nelarabine (Winter et al, 2015) . These initial safety data suggest that this ara-G prodrug is better tolerated by treatment-na€ ıve patients than by those who are treatment refractory or who have relapsed (National Comprehensive Cancer Network, 2015) . The efficacy data may establish whether the inclusion of nelarabine with the COG aBFM regimen improves outcome among paediatric and young adult patients with previously untreated T-ALL.
Finally, a phase 1, open-label, dose-escalation trial in which nelarabine was tested as part of a multiagent chemotherapy regimen (with cyclophosphamide and etoposide; NCT00981799) in paediatric and young adult patients (1-21 years, n = 19) with relapsed T-ALL or T-LBL found that the combination was effective, with levels of activity and toxicity that were comparable with those of established reinduction regimens in this patient population (Whitlock et al, 2014) .
Limitations
The main limitations of this study are that it was an openlabel, observational trial without a comparator arm, and was conducted in a small number of patients. In addition, the study was not designed to address the safety of nelarabine in patients treated in combination with other agents or with earlier lines of therapy for T-ALL or T-LBL. Although the planned enrolment was 40 patients, enrolment difficulties were encountered, probably because of the rarity of the required patient population [age-adjusted incidence for ALL in the USA, 1Á77 per 100 000 individuals per year (National Comprehensive Cancer Network, 2015) ], the good prognosis with frontline treatment and the fact that relapsed or refractory paediatric patients may be treated with nelarabine combined with other chemotherapy regimens [e.g. NECTAR, NCT00981799 (Whitlock et al, 2014) ]. However, since this was a phase 4 observational study, the findings should be generalizable to paediatric patients with relapsed/refractory T-ALL or T-LBL. Finally, no attempt was made to independently confirm the recorded tumour responses.
Conclusions
In this observational, post-authorisation study, the response rate and median OS were comparable with, or even better than, prior clinical studies of nelarabine monotherapy in this disease setting. There were no new or unexpected safety findings; reported AEs and the incidence and severity of neurological changes were consistent with the published clinical experience with nelarabine, and many resolved following treatment. However, previously identified potential risk factors for nelarabine-associated neurological toxicity did not appear to be predictive of neurological toxicity in this small number of patients. The risk-benefit profile of nelarabine in children and young adults (≤21 years of age) with relapsed or refractory T-ALL and T-LBL remains positive.
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